Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
Avery
Robert L
RL
California Retina Consultants and Research Foundation, Santa Barbara, California 93103, USA. avery1@jhu.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab